Imatinib Resistant Gastrointestinal Stromal Tumors Therapeutics
1. Sutent patent expiration
Treatment: Treatment of protein kinase related disorders, such as gastrointestinal stromal tumors, renal cell carcinoma and advanced pancreatic neuroendocrine tumors, with sunitinib; Treatment of gastrointestina...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7125905 (Pediatric) | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug, 2021
(4 years ago) | |
|
US6573293 (Pediatric) | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug, 2021
(4 years ago) | |
|
US7211600 (Pediatric) | CPPI CV | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Jun, 2021
(4 years ago) | |
| US6573293 | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb, 2021
(4 years ago) | |
| US7211600 | CPPI CV | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Dec, 2020
(5 years ago) | |
| US7125905 | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-639) | May 20, 2014 |
| New Indication(I-755) | Nov 16, 2020 |
| Pediatric Exclusivity(PED) | May 16, 2021 |
Drugs and Companies using SUNITINIB MALATE ingredient
Market Authorisation Date: 26 January, 2006
Dosage: CAPSULE
How can I launch a generic of SUTENT before it's drug patent expiration?
More Information on Dosage
SUTENT family patents
